Core Viewpoint - ST HuLuWa (605199.SH) aims to enhance its core competitiveness and accelerate drug development by integrating R&D resources and sharing R&D risks through a technical cooperation agreement with related parties [1] Group 1: Company Actions - The company held a special meeting of independent directors and an extraordinary board meeting on October 17, 2025, to approve the proposal for signing a technical cooperation development contract [1] - The expected total R&D cost for the projects "Ondansetron Oral Soluble Film" and "Ibutamoren Right-Arm Injection Concentrate Solution" is budgeted to not exceed 11.25 million yuan [1] - Following board approval, the company will sign a technical cooperation development contract with Kang Lianxian to jointly develop the aforementioned projects [1]

北京市在城区建国门内大街26号新闻大厦7层、8层 邮编:100005 电话: 010-88004488/66090088 传真:010-66090016 北京国枫律师事务所 关于海南葫芦娃药业集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025]A0507 号 致: 海南葫芦娃药业集团股份有限公司 (贵公司) 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托,指派律师出席并见 证贵公司2025年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《海 南葫芦娃药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次 会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等 ...

Core Viewpoint - ST Huluwawa (605199) announced on October 17 that it plans to sign two technology cooperation development contracts with its affiliate Hangzhou Kanglixian Pharmaceutical Technology Co., Ltd. to jointly develop "Ondansetron Oral Soluble Film" and "Ibandronate Sodium Injection Concentrate Solution" projects, with a total estimated contract amount of 11.25 million yuan [1] Group 1 - The company intends to collaborate on two specific pharmaceutical projects [1] - The estimated contract amounts for the projects are 9.1 million yuan and 2.15 million yuan respectively [1] - The total estimated contract value for both projects is 11.25 million yuan [1]

Group 1 - The Hainan Free Trade Zone concept rose by 2.58%, ranking first among concept sectors, with 22 stocks increasing, including Haixia Co., Haima Automobile, and ST Huawen hitting the daily limit [1][2] - Notable gainers included Haikou Group, Hainan Haiyao, and Kangzhi Pharmaceutical, which rose by 6.38%, 6.14%, and 5.69% respectively [1] - The stocks with the largest declines were Hainan Huatie, Junda Co., and *ST Shuangcheng, which fell by 1.30%, 1.23%, and 1.06% respectively [1] Group 2 - The Hainan Free Trade Zone concept saw a net inflow of 358 million yuan from main funds, with 18 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan [2] - The top net inflow stock was Haixia Co., with a net inflow of 108 million yuan, followed by HNA Holding, Hainan Development, and Haide Co. with net inflows of 89.09 million yuan, 82.73 million yuan, and 64.19 million yuan respectively [2][3] - The highest net inflow ratios were seen in Haide Co., ST Huawen, and Hainan Haiyao, with ratios of 14.30%, 13.37%, and 12.49% respectively [3] Group 3 - The top stocks in the Hainan Free Trade Zone concept included Haixia Co. with a daily increase of 10.03% and a turnover rate of 6.55%, followed by HNA Holding with a 1.80% increase and a turnover rate of 2.30% [3][4] - Other notable performers included Hainan Development with a 2.99% increase and a turnover rate of 8.46%, and Haikou Group with a 6.38% increase and a turnover rate of 7.54% [4] - Stocks such as Hainan Huatie and Junda Co. experienced declines of 1.30% and 1.23% respectively, with negative main fund flows [4]

Core Points - The company has elected Mr. Wang Qingtao as the employee representative director for the fourth board of directors [1] - Mr. Wang's term will align with the term of the fourth board of directors, which consists of 7 members [1] - The election was conducted during the employee representative assembly held on October 15, 2025 [1] Summary by Sections Election Announcement - The company announced the election of Mr. Wang Qingtao as the employee representative director [1] - The decision was made during the employee representative assembly with voting from attending employee representatives [1] Board Composition - The fourth board of directors will include 3 non-independent directors, 3 independent directors, and Mr. Wang as the employee representative director [1] - The total number of directors will not exceed the legal requirement of having employee representatives not surpassing half of the total board members [1] Qualifications of Mr. Wang Qingtao - Mr. Wang meets the qualifications and conditions for the position as per the Company Law and the company's articles of association [1] - His professional background includes various roles in human resources and administration within the company and other organizations [3] - Mr. Wang holds 273,900 shares of the company, representing 0.07% of the total share capital, and has no related party relationships with major shareholders [4]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-075 海南葫芦娃药业集团股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日 召开职工代表大会，经与会职工代表表决，通过如下决议： 选举王清涛先生（简历附后）担任公司第四届董事会职工代表董事。王清涛先 生将与公司 2025 年第二次临时股东大会选举产生的 3 名非独立董事及 3 名独立董事 共同组成公司第四届董事会。任期与公司第四届董事会任期一致。 王清涛先生符合《公司法》、《公司章程》中有关职工代表董事任职的资格和条 件。其担任第四届董事会职工代表董事后，公司董事会成员数量为 7 名，其中兼任 公司高级管理人员以及由职工代表担任的董事人数总计不超过公司董事总数的二分 之一，符合相关法律法规及规范性文件的要求。 特此公告。 海南葫芦娃药业集团股份有限公司董事会 1 附： 王清涛先生简历 王清涛：男，1982 年出生，中国国籍 ...

海南葫芦娃药业集团股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 10 月 目 录 | 2025 | 年第二次临时股东大会会议议程 | 2 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议须知 | 4 | | 议案一: | 关于取消监事会并修订《公司章程》及其附件的议案 5 | | | 议案二: | 关于修订《公司独立董事工作制度》的议案 7 | | | 议案三: | 关于修订《公司重大经营与投资管理制度》的议案 | 8 | | 议案四: | 关于修订《公司融资与对外担保管理制度》的议案 | 9 | | 议案五: | 关于修订《公司关联交易管理办法》的议案 10 | | | | 议案六:关于修订《公司董事、高级管理人员薪酬管理制度》的议案 11 | | | 议案七: | 关于修订《公司会计师事务所选聘制度》的议案 12 | | | 议案八: | 关于选举第四届董事会非独立董事的议案 | 13 | | 议案九: | 关于选举第四届董事会独立董事的议案 | 14 | 1 海南葫芦娃药业集团股份有限公司 2025 年第二次临时股东大会会议议程 会议时间：2 ...

Core Viewpoint - The article highlights the significant contributions of Liu Jiaqi, a prominent volcanologist in China, who has advanced the understanding of volcanic activity and its implications for both scientific research and societal progress [4][18][21]. Group 1: Contributions to Volcanology - Liu Jiaqi is recognized as China's first academician in the field of volcanology, having established the existence and characteristics of volcanoes in China, countering the international misconception that China lacks volcanoes [4][21]. - He has published comprehensive works, including "Chinese Volcanoes," which systematically details the temporal and spatial distribution of volcanoes in China [21][25]. - Liu has linked volcanic activity to climate change, emphasizing its role as a significant factor in climate variations [23]. Group 2: Research and Exploration - Liu Jiaqi has conducted extensive field research across China, visiting 34 provinces and regions to gather evidence of volcanic activity [21]. - His research has led to the discovery of maar lakes, which serve as excellent indicators for studying ancient climates and environments [23]. - He has engaged in international research collaborations, bringing global attention to Chinese volcanology and hosting influential volcanic conferences in China [25]. Group 3: Innovation and Application - Liu has pioneered the conversion of basalt, a product of volcanic eruptions, into basalt fiber, which has significant commercial value, increasing its worth from approximately 50-60 yuan per ton to 20,000-100,000 yuan after processing [35]. - The basalt fiber has been utilized in advanced applications, including the production of materials for space exploration, such as the flag used in the Chang'e 6 lunar mission, which can withstand extreme temperatures [39]. Group 4: Public Engagement and Education - Liu Jiaqi has actively engaged in science communication, producing over 200 educational videos that have garnered a large following, making complex geological concepts accessible to the public [44]. - His dedication to education and outreach reflects a commitment to fostering a greater understanding of geology and its relevance to society [44].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）2024年度内部控制被 出具否定意见审计报告，根据《上海证券交易所股票上市规则》第9.8.1条规定，公司 股票于2025年4月30日起被实施其他风险警示。 ● 根据《上海证券交易所股票上市规则》第9.8.5条："上市公司股票因第9.8.1 条第一款第（二）项至第（五）项规定情形被实施其他风险警示的，在被实施其他风险 警示期间，公司应当至少每月披露1次提示性公告，分阶段披露涉及事项的解决进展情 况"。公司将每月披露一次其他风险警示相关事项的进展情况，提示相关风险。 一、关于公司被实施其他风险警示的基本情况 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-074 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 2、公司持续组织开展内部控制及各项管理制度的内部自查，进一步强化内控管理。 通过内部协同监督，对公司近期新签订的合同进行了风险排查，严格规范合同签订前的 ...

投资者关系管理办法 第一章 总则 第一条 为了加强公司与投资者和潜在投资者之间的沟通，增进投资者对公司 的了解，倡导理性投资，促进公司治理结构的改善，提升公司投资价值，根据《中 华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易所股票上 市规则》（以下简称《股票上市规则》）、《上市公司投资者关系管理工作指引》 和《公司章程》及其他相关法律、法规的规定，结合本公司实际情况，制定本制 度。 第二条 投资者关系管理工作是指公司通过便利股东权利行使、信息披露、 互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资 者对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第二章 投资者关系管理的基本原则和宗旨 第三条 公司投资者关系管理工作应当遵循公开、公平、公正原则，真实、 准确、完整地介绍和反映公司的实际状况。公司应当避免在投资者关系活动中出 现发布或者泄露未公开重大信息、过度宣传误导投资者决策、对公司股票及其衍 生品种价格作出预期或者承诺等违反信息披露规则或者涉嫌操纵股票及其衍生 品种价格的行为。 第四条 投资者关系管理的基本 ...